Oxford Biomedica plc (LSE:OXB) confirmed a manufacturing and supply partnership with Aura Biosciences (NASDAQ:AURA) to support Phase 3 development and preparations for potential commercial production of an experimental treatment for ocular cancers. The agreement, established earlier in 2026, covers development and manufacturing activities for Aura’s lead virus-like drug conjugate (VDC) candidate, belzupacap sarotalocan (bel-sar).
Aura Biosciences offers a fully funded ocular oncology play with a Phase 3 upside and limited financing risk. Click to read more on AURA here.
BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers, today announced that Natalie Holles, CEO and President, will participate in the following upcoming investor conference: Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16, 2026.Fireside Chat at 2:35 p.m. ET The live webcast of the fireside chat will
BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA) (“Aura” or the “Company”), a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers, today announced that inducement equity awards (collectively, “Inducement Awards”) were granted to Erica Kratz, Ph.D., Aura’s new Chief Regulatory and Quality Officer, Susan Abu-Absi, Ph.D., Aura’s new Chief Operating Officer, and Julie Person, Aura’s new C
This is the newest page. Registered accounts read further back.